Yaribeygi, Habib

Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

Ferrari, A. J., Santomauro, D. F., Aali, A., Abate, Y. H., Abbafati, C., Abbastabar, H., Abd ElHafeez, S., Abdelmasseh, M., Abd-Elsalam, S., Abdollahi, A., et al. (2024) · The Lancet

Global Health and EpidemiologyInsurance, Mortality, Demography, Risk Management

Cited by 5,112

Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

Naghavi, M., Ong, K. L., Aali, A., Ababneh, H. S., Abate, Y. H., Abbafati, C., Abbasgholizadeh, R., Abbasian, M., Abbasi-Kangevari, M., Abbastabar, H., et al. (2024) · The Lancet

Insurance, Mortality, Demography, Risk ManagementGlobal Health and Epidemiology

Cited by 2,889

Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021

Brauer, M., Roth, G. A., Aravkin, A. Y., Zheng, P., Abate, K. H., Abate, Y. H., Abbafati, C., Abbasgholizadeh, R., Abbasi, M. A., Abbasian, M., et al. (2024) · The Lancet

Cardiovascular Health and Risk FactorsGlobal Public Health Policies and Epidemiology

Cited by 2,884

Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021

Ng, M., Gakidou, E., Lo, J., Abate, Y. H., Abbafati, C., Abbas, N., Abbasian, M., Abd ElHafeez, S., Abdel-Rahman, W. M., Abd-Elsalam, S., et al. (2025) · The Lancet

Obesity, Physical Activity, DietDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 1,151

Insulin resistance: review of the underlying molecular mechanisms

Yaribeygi, H., Farrokhi, F. R., Butler, A. E., & Sahebkar, A. (2019) · Journal of Cellular Physiology

Metabolism, Diabetes, and CancerAdipokines, Inflammation, and Metabolic Diseases

Cited by 929

Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021

Bhattacharjee, N. V., Schumacher, A. E., Aali, A., Abate, Y. H., Abbasgholizadeh, R., Abbasian, M., Abbasi-Kangevari, M., Abbastabar, H., Abd ElHafeez, S., Abd-Elsalam, S., et al. (2024) · The Lancet

Insurance, Mortality, Demography, Risk ManagementDemographic Trends and Gender Preferences

Cited by 629

Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023

Naghavi, M., Kyu, H. H., A, B., Aalipour, M. A., Aalruz, H., Ababneh, H. S., Abafita, B. J., Abaraogu, U. O., Abbafati, C., Abbasi, M., et al. (2025) · The Lancet

Insurance, Mortality, Demography, Risk ManagementGlobal Health and Epidemiology

Cited by 595

Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the Global Burden of Disease Study 2023

Schumacher, A. E., Zheng, P., Barber, R. M., A, B., Aalipour, M. A., Aalruz, H., Ababneh, H. S., Abaraogu, U. O., Abbafati, C., Abbas, N., et al. (2025) · The Lancet

Insurance, Mortality, Demography, Risk ManagementGlobal Cancer Incidence and Screening

Cited by 209

Sodium—Glucose cotransporter inhibitors and oxidative stress: An update

Yaribeygi, H., Atkin, S. L., Butler, A. E., & Sahebkar, A. (2019) · Journal of Cellular Physiology

Diabetes Treatment and ManagementNitric Oxide and Endothelin Effects

Cited by 167

GLP-1 mimetics and cognition.

Yaribeygi, H., Rashidy-Pour, A., Atkin, S. L., Jamialahmadi, T., & Sahebkar, A. (2021) · Life Sciences

Diabetes Treatment and ManagementAlzheimer's disease research and treatments

Cited by 96

Pathophysiology of Physical Inactivity-Dependent Insulin Resistance: A Theoretical Mechanistic Review Emphasizing Clinical Evidence

Yaribeygi, H., Maleki, M., Sathyapalan, T., Jamialahmadi, T., & Sahebkar, A. (2021) · Journal of Diabetes Research

Physical Activity and HealthMetabolism, Diabetes, and Cancer

Cited by 91

Protective effects of plant‐derived natural products on renal complications

Yaribeygi, H., Simental‐Mendía, L. E., Butler, A. E., & Sahebkar, A. (2019) · Journal of Cellular Physiology

Natural Antidiabetic Agents StudiesChronic Kidney Disease and Diabetes

Cited by 46

The effects of glucagon-like peptide-1 receptor agonists and dipeptydilpeptidase-4 inhibitors on blood pressure and cardiovascular complications in diabetes

Yaribeygi, H., Farrokhi, F. R., Abdalla, M. A., Sathyapalan, T., Banach, M., Jamialahmadi, T., & Sahebkar, A. (2021) · Journal of Diabetes Research

Diabetes Treatment and ManagementBlood Pressure and Hypertension Studies

Cited by 31

GLP-1 mimetics and diabetic ketoacidosis: possible interactions and clinical consequences

Forouzanmehr, B., Hemmati, M. A., Atkin, S. L., Jamialahmadi, T., Yaribeygi, H., & Sahebkar, A. (2025) · Naunyn-Schmiedeberg's Archives of Pharmacology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 3